Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma

International Journal of Cancer

Volumn 129, Issue 4, 2011, Pages 993-1005

  Iwahori, Kota ^a,b   Serada, Satoshi ^a   Fujimoto, Minoru ^a   Nomura, Shintaro ^c   Osaki, Tadashi ^b   Lee, Chun Man ^d   Mizuguchi, Hiroyuki ^a   Takahashi, Tsuyoshi ^a   Ripley, Barry ^b   Okumura, Meinoshin ^b   Kawase, Ichiro ^b   Kishimoto, Tadamitsu ^b   Naka, Tetsuji ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

^d OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

gene therapy; malignant pleural mesothelioma; p53; signal transducer and activator of transcription 3; suppressor of cytokine signaling 3

Indexed keywords

ADENOVIRUS VECTOR; FOCAL ADHESION KINASE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; REPLICATION DEFECTIVE RECOMBINANT ADENOVIRUS VECTOR; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL STRAIN EHMES 1; CELL STRAIN H226; CELL STRAIN MESO 1; CELL STRAIN MESO 4; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURA MESOTHELIOMA; MITOSIS INHIBITION; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 79959686336     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25716     Document Type: Article

References (44)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P,. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44. (Pubitemid 46606305)
2. Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E,. The Mesothelioma epidemic in Western Europe: an update. Br J Cancer 2004; 90: 1022-4. (Pubitemid 38495822)
3. Leigh J, Driscoll T,. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003; 9: 206-17. (Pubitemid 40292088)
4. Leithner K, Leithner A, Clar H, Weinhaeusel A, Radl R, Krippl P, Rehak P, Windhager R, Haas OA, Olschewski H,. Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40. Orphanet J Rare Dis 2006; 1: 44.
5. Murayama T, Takahashi K, Natori Y, Kurumatani N,. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 2006; 49: 1-7. (Pubitemid 43083291)
6. Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H,. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995; 12: 455-60.
7. Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB,. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999; 59: 367-71. (Pubitemid 29048869)
8. Lee TC, Zhang Y, Aston C, Hintz R, Jagirdar J, Perle MA, Burt M, Rom WN,. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 1993; 53: 2858-64. (Pubitemid 23180528)
9. Morocz IA, Schmitter D, Lauber B, Stahel RA,. Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway. Br J Cancer 1994; 70: 850-6. (Pubitemid 24331076)
10. Versnel MA, Claesson-Welsh L, Hammacher A, Bouts MJ, van der Kwast TH, Eriksson A, Willemsen R, Weima SM, Hoogsteden HC, Hagemeijer A, et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 1991; 6: 2005-11. (Pubitemid 21924040)
11. Monti G, Jaurand MC, Monnet I, Chretien P, Saint-Etienne L, Zeng L, Portier A, Devillier P, Galanaud P, Bignon J, et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment. Cancer Res 1994; 54: 4419-23. (Pubitemid 24273156)
12. Adachi Y, Aoki C, Yoshio-Hoshino N, Takayama K, Curiel DT, Nishimoto N,. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer 2006; 119: 1303-11. (Pubitemid 44258804)
13. Buettner R, Mora LB, Jove R,. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-54. (Pubitemid 35177340)
14. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387: 921-4. (Pubitemid 27289595)
15. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T,. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-9. (Pubitemid 27289596)
16. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ,. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387: 917-21. (Pubitemid 27289594)
17. Rakesh K, Agrawal DK,. Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol 2005; 70: 649-57. (Pubitemid 41058699)
18. Naka T, Fujimoto M, Tsutsui H, Yoshimura A,. Negative regulation of cytokine and TLR signalings by SOCS and others. Adv Immunol 2005; 87: 61-122. (Pubitemid 41135899)
19. Yoshimura A, Naka T, Kubo M,. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7: 454-65. (Pubitemid 46834848)
20. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, Silva A, Asimakis M, Farley A, Nash AD, Metcalf D, Hilton DJ, et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 2000; 97: 6493-8. (Pubitemid 30412741)
21. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM,. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 2003; 100: 14133-8. (Pubitemid 37499203)
22. Bromberg J,. Stat proteins and oncogenesis. J Clin Invest 2002; 109: 1139-42. (Pubitemid 34496590)
23. Sekido Y,. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 2010; 101: 1-6.
24. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR,. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006; 25: 5960-8. (Pubitemid 44477290)
25. Lehmann U, Schmitz J, Weissenbach M, Sobota RM, Hortner M, Friederichs K, Behrmann I, Tsiaris W, Sasaki A, Schneider-Mergener J, Yoshimura A, Neel BG, et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 2003; 278: 661-71. (Pubitemid 36043620)
26. Liu E, Cote JF, Vuori K,. Negative regulation of FAK signaling by SOCS proteins. EMBO J 2003; 22: 5036-46. (Pubitemid 37222024)
27. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T, Yoshikawa H,. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005; 24: 6406-17. (Pubitemid 41486474)
28. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I,. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 1996; 93: 1320-4.
29. Kijima T, Osaki T, Nishino K, Kumagai T, Funakoshi T, Goto H, Tachibana I, Tanio Y, Kishimoto T,. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res 1999; 59: 4906-11. (Pubitemid 29472895)
30. Goto H, Osaki T, Kijima T, Nishino K, Kumagai T, Funakoshi T, Kimura H, Takeda Y, Yoneda T, Tachibana I, Hayashi S,. Gene therapy utilizing the Cre/loxP system selectively suppresses tumor growth of disseminated carcinoembryonic antigen-producing cancer cells. Int J Cancer 2001; 94: 414-9. (Pubitemid 32906074)
31. Nishino K, Osaki T, Kumagai T, Kijima T, Tachibana I, Goto H, Arai T, Kimura H, Funakoshi T, Takeda Y, Tanio Y, Hayashi S,. Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a Myc-Max binding motif. Int J Cancer 2001; 91: 851-6. (Pubitemid 32178656)
32. Kanegae Y, Makimura M, Saito I,. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 1994; 47: 157-66. (Pubitemid 24330700)
33. Lipka DB, Hoffmann LS, Heidel F, Markova B, Blum MC, Breitenbuecher F, Kasper S, Kindler T, Levine RL, Huber C, Fischer T,. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther 2008; 7: 1176-84.
34. Verstovsek S, Manshouri T, Quintas-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z,. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 2008; 14: 788-96. (Pubitemid 351231161)
35. Vazquez A, Bond EE, Levine AJ, Bond GL,. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008; 7: 979-87.
36. Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K,. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006; 118: 812-20. (Pubitemid 43157656)
37. Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella E, Xie D,. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 1997; 36: 10117-24. (Pubitemid 27357721)
38. Hao M, Lowy AM, Kapoor M, Deffie A, Liu G, Lozano G,. Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem 1996; 271: 29380-5. (Pubitemid 26382655)
39. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002; 4: 11-9.
40. Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E, Anderson CW,. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem 2002; 277: 12491-4. (Pubitemid 34952604)
41. Abbas T, Dutta A,. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-14.
42. Calabrese V, Mallette FA, Deschenes-Simard X, Ramanathan S, Gagnon J, Moores A, Ilangumaran S, Ferbeyre G,. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell 2009; 36: 754-67.
43. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13: 4456-66. (Pubitemid 47219714)
44. Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P, Amin KM, Litzky LA, Wilson JM, Kaiser LR, Albelda SM,. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444-53. (Pubitemid 41507705)